Otsuka Pharmaceutical has announced plans to acquire Transcend Therapeutics in a deal valued at up to $1.225 billion, strengthening its presence in the neuropsychiatric treatment space and advancing its pipeline of next-generation therapies.
The agreement, which will be executed through Otsuka’s U.S. subsidiary, is expected to close in the second quarter of 2026, pending customary regulatory approvals and closing conditions. Under the terms, Otsuka will pay $700 million upfront to Transcend shareholders, with an additional $525 million tied to future sales milestones related to the company’s investigational assets.
At the center of the acquisition is Transcend’s lead candidate, TSND-201 (methylone), a rapid-acting neuroplastogen being developed as a potential treatment for post-traumatic stress disorder (PTSD) and other psychiatric conditions. The therapy is designed to enhance neuroplasticity—the brain’s ability to reorganize neural connections—which plays a critical role in memory, emotional regulation, and recovery from trauma.
PTSD remains a major unmet medical need, with more than 13 million individuals affected annually in the United States alone. Despite this high prevalence, no new treatments have been approved for the condition in over two decades, leaving patients reliant on psychotherapy and existing antidepressant medications.
TSND-201 works by targeting monoamine transporters in the brain, including serotonin, norepinephrine, and dopamine systems, to increase neurotransmitter levels and promote rapid and sustained neural plasticity. Notably, the compound does not act on the serotonin 5-HT2A receptor, which is associated with hallucinogenic effects, making it a non-hallucinogenic alternative among emerging neuropsychiatric therapies.
The investigational therapy has already shown promising results in a Phase 2 clinical trial known as IMPACT-1, involving adults with PTSD. Findings from the study, published in JAMA Psychiatry in early 2026, demonstrated favorable outcomes, contributing to the therapy receiving Breakthrough Therapy designation from the U.S. Food and Drug Administration in 2025. A Phase 3 trial is currently underway in the United States, with patient recruitment in progress.
In addition to TSND-201, Transcend is advancing a pipeline of novel prodrugs aimed at improving efficacy, safety, and tolerability. These efforts are currently in preclinical development, with plans to submit an Investigational New Drug application to the FDA.
Otsuka, which has a long-standing focus on psychiatric and neurological disorders such as schizophrenia, bipolar disorder, and depression, sees the acquisition as a strategic move to expand its portfolio with innovative mechanisms of action. By integrating Transcend’s capabilities and scientific expertise, the company aims to accelerate the development of new therapies and address significant gaps in mental health treatment.
The deal also reflects a broader industry trend toward investing in novel approaches that target underlying brain biology, particularly in areas where treatment innovation has lagged. With this acquisition, Otsuka aims to position itself at the forefront of next-generation neuropsychiatric drug development.